Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

Antidiabetic drugs influence molecular mechanisms in prostate cancer.

Pircher A, Zieher M, Eigentler A, Pichler R, Schäfer G, Fritz J, Puhr M, Steiner E, Horninger W, Klocker H, Heidegger I.

Cancer Biol Ther. 2018 Aug 1:1-9. doi: 10.1080/15384047.2018.1491490. [Epub ahead of print]

PMID:
30067448
2.

Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1α Upregulation in PTEN Negative Prostate Cancer Cells.

Weber A, Klocker H, Oberacher H, Gnaiger E, Neuwirt H, Sampson N, Eder IE.

Int J Mol Sci. 2018 Jul 21;19(7). pii: E2129. doi: 10.3390/ijms19072129.

3.

Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients.

Lieb V, Weigelt K, Scheinost L, Fischer K, Greither T, Marcou M, Theil G, Klocker H, Holzhausen HJ, Lai X, Vera J, Ekici AB, Horninger W, Fornara P, Wullich B, Taubert H, Wach S.

Oncotarget. 2017 Dec 30;9(12):10402-10416. doi: 10.18632/oncotarget.23781. eCollection 2018 Feb 13.

4.

Inhibition of Nox4-dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal-mediated protumorigenic interactions.

Sampson N, Brunner E, Weber A, Puhr M, Schäfer G, Szyndralewiez C, Klocker H.

Int J Cancer. 2018 Jul 15;143(2):383-395. doi: 10.1002/ijc.31316. Epub 2018 Mar 1.

5.

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.

Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, Culig Z, Van der Pluijm G, Klocker H.

Clin Cancer Res. 2018 Feb 15;24(4):927-938. doi: 10.1158/1078-0432.CCR-17-0989. Epub 2017 Nov 20.

PMID:
29158269
6.

Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.

Pichler R, Fritz J, Tulchiner G, Klinglmair G, Soleiman A, Horninger W, Klocker H, Heidegger I.

BJU Int. 2018 Jan;121(1):29-37. doi: 10.1111/bju.14019. Epub 2017 Oct 12.

PMID:
28941000
7.

Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells.

Shi X, Peng Y, Du X, Liu H, Klocker H, Lin Q, Shi J, Zhang J.

Prostate. 2017 Oct;77(14):1424-1437. doi: 10.1002/pros.23404. Epub 2017 Aug 29.

PMID:
28850686
8.

Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.

Mühlberger N, Boskovic K, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Sroczynski G, Siebert U.

BMC Public Health. 2017 Jun 26;17(1):596. doi: 10.1186/s12889-017-4439-9.

9.

ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study.

Heidegger I, Klocker H, Pichler R, Pircher A, Prokop W, Steiner E, Ladurner C, Comploj E, Lunacek A, Djordjevic D, Pycha A, Plas E, Horninger W, Bektic J.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):271-275. doi: 10.1038/pcan.2017.3. Epub 2017 Mar 21.

PMID:
28322234
10.

Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer.

Pichler R, Fritz J, Heidegger I, Steiner E, Culig Z, Klocker H, Fuchs D.

Cancer Sci. 2017 Apr;108(4):663-670. doi: 10.1111/cas.13171. Epub 2017 Apr 12.

11.

Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture.

Eder T, Weber A, Neuwirt H, Grünbacher G, Ploner C, Klocker H, Sampson N, Eder IE.

Int J Mol Sci. 2016 Sep 1;17(9). pii: E1458. doi: 10.3390/ijms17091458.

12.

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.

Hoefer J, Akbor M, Handle F, Ofer P, Puhr M, Parson W, Culig Z, Klocker H, Heidegger I.

Oncotarget. 2016 Sep 13;7(37):59781-59794. doi: 10.18632/oncotarget.10926.

13.

A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.

Castelo-Branco P, Leão R, Lipman T, Campbell B, Lee D, Price A, Zhang C, Heidari A, Stephens D, Boerno S, Coelho H, Gomes A, Domingos C, Apolonio JD, Schäfer G, Bristow RG, Schweiger MR, Hamilton R, Zlotta A, Figueiredo A, Klocker H, Sültmann H, Tabori U.

Oncotarget. 2016 Sep 6;7(36):57726-57736. doi: 10.18632/oncotarget.10639.

14.

High prevalence of side population in human cancer cell lines.

Boesch M, Zeimet AG, Fiegl H, Wolf B, Huber J, Klocker H, Gastl G, Sopper S, Wolf D.

Oncoscience. 2016 Apr 10;3(3-4):85-87. doi: 10.18632/oncoscience.300. eCollection 2016.

15.

GPR30 Promotes Prostate Stromal Cell Activation via Suppression of ERα Expression and Its Downstream Signaling Pathway.

Jia B, Gao Y, Li M, Shi J, Peng Y, Du X, Klocker H, Sampson N, Shen Y, Liu M, Zhang J.

Endocrinology. 2016 Aug;157(8):3023-35. doi: 10.1210/en.2016-1035. Epub 2016 May 10.

PMID:
27163843
16.

Oxidative phosphorylation and mitochondrial function differ between human prostate tissue and cultured cells.

Schöpf B, Schäfer G, Weber A, Talasz H, Eder IE, Klocker H, Gnaiger E.

FEBS J. 2016 Jun;283(11):2181-96. doi: 10.1111/febs.13733. Epub 2016 Apr 29.

17.

Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.

Schlick B, Massoner P, Lueking A, Charoentong P, Blattner M, Schaefer G, Marquart K, Theek C, Amersdorfer P, Zielinski D, Kirchner M, Trajanoski Z, Rubin MA, Müllner S, Schulz-Knappe P, Klocker H.

PLoS One. 2016 Feb 10;11(2):e0147739. doi: 10.1371/journal.pone.0147739. eCollection 2016.

18.

A P-H Functionalized Al/P Frustrated Lewis Pair: Substrate Activation and Selective Hydrogen Transfer.

Keweloh L, Klöcker H, Würthwein EU, Uhl W.

Angew Chem Int Ed Engl. 2016 Feb 24;55(9):3212-5. doi: 10.1002/anie.201511048. Epub 2016 Feb 2.

PMID:
26836748
19.

Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.

Ofer P, Heidegger I, Eder IE, Schöpf B, Neuwirt H, Geley S, Klocker H, Massoner P.

Mol Endocrinol. 2015 Dec;29(12):1694-707. doi: 10.1210/me.2015-1073. Epub 2015 Oct 9.

20.

Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.

Bu H, Narisu N, Schlick B, Rainer J, Manke T, Schäfer G, Pasqualini L, Chines P, Schweiger MR, Fuchsberger C, Klocker H.

Hum Mutat. 2016 Jan;37(1):52-64. doi: 10.1002/humu.22909. Epub 2015 Oct 19.

22.

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.

Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z, Baniahmad A.

Oncotarget. 2015 Nov 3;6(34):35542-55. doi: 10.18632/oncotarget.4689. Review.

23.

Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?

Heidegger I, Höfer J, Luger M, Pichler R, Klocker H, Horninger W, Steiner E, Jochberger S, Culig Z.

Prostate. 2015 Dec;75(16):1904-9. doi: 10.1002/pros.23086. Epub 2015 Aug 26.

PMID:
26306920
24.

Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate.

Dueregger A, Schöpf B, Eder T, Höfer J, Gnaiger E, Aufinger A, Kenner L, Perktold B, Ramoner R, Klocker H, Eder IE.

PLoS One. 2015 Aug 18;10(8):e0135704. doi: 10.1371/journal.pone.0135704. eCollection 2015.

25.

Validation of Next-Generation Sequencing of Entire Mitochondrial Genomes and the Diversity of Mitochondrial DNA Mutations in Oral Squamous Cell Carcinoma.

Kloss-Brandstätter A, Weissensteiner H, Erhart G, Schäfer G, Forer L, Schönherr S, Pacher D, Seifarth C, Stöckl A, Fendt L, Sottsas I, Klocker H, Huck CW, Rasse M, Kronenberg F, Kloss FR.

PLoS One. 2015 Aug 11;10(8):e0135643. doi: 10.1371/journal.pone.0135643. eCollection 2015.

26.

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.

Puhr M, Hoefer J, Eigentler A, Dietrich D, van Leenders G, Uhl B, Hoogland M, Handle F, Schlick B, Neuwirt H, Sailer V, Kristiansen G, Klocker H, Culig Z.

Oncogene. 2016 May 5;35(18):2322-32. doi: 10.1038/onc.2015.292. Epub 2015 Aug 10.

27.

The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.

Heidegger I, Massoner P, Sampson N, Klocker H.

Cancer Lett. 2015 Oct 28;367(2):113-21. doi: 10.1016/j.canlet.2015.07.026. Epub 2015 Jul 29. Review.

PMID:
26231734
28.

Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program.

Heidegger I, Fritz J, Klocker H, Pichler R, Bektic J, Horninger W.

PLoS One. 2015 Jul 28;10(7):e0134134. doi: 10.1371/journal.pone.0134134. eCollection 2015.

29.

Alkynyl functionalized Al/P-based frustrated Lewis pairs - aluminium alkynide elimination and evidence for the formation of 3H-phosphaallenes [R-P=C=C(H)-(t)Bu].

Klöcker H, Roters S, Hepp A, Uhl W.

Dalton Trans. 2015 Jul 28;44(28):12670-9. doi: 10.1039/c5dt01607j. Epub 2015 Jun 17.

PMID:
26084038
30.

miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.

Pasqualini L, Bu H, Puhr M, Narisu N, Rainer J, Schlick B, Schäfer G, Angelova M, Trajanoski Z, Börno ST, Schweiger MR, Fuchsberger C, Klocker H.

Mol Endocrinol. 2015 Jul;29(7):1037-54. doi: 10.1210/me.2014-1358. Epub 2015 Jun 8.

31.

PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.

Heidegger I, Klocker H, Pichler R, Horninger W, Bektic J.

Anticancer Res. 2015 Jun;35(6):3567-70.

PMID:
26026127
32.

The ONCOTYROL Prostate Cancer Outcome and Policy Model: Effect of Prevalence Assumptions on the Benefit-Harm Balance of Screening.

Mühlberger N, Kurzthaler C, Iskandar R, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Conrads-Frank A, Sroczynski G, Siebert U.

Med Decis Making. 2015 Aug;35(6):758-72. doi: 10.1177/0272989X15585114. Epub 2015 May 14.

PMID:
25977360
33.

Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot.

Pichler R, Borena W, Schäfer G, Manzl C, Culig Z, List S, Neururer S, Von Laer D, Heidegger I, Klocker H, Horninger W, Steiner H, Brunner A.

World J Urol. 2015 Dec;33(12):2145-51. doi: 10.1007/s00345-015-1539-y. Epub 2015 Mar 19.

PMID:
25786709
34.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.

Santer FR, Erb HH, Oh SJ, Handle F, Feiersinger GE, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane JK, Maitland NJ, Klocker H, Eder IE, Culig Z.

Oncotarget. 2015 Mar 20;6(8):6105-22.

35.

Patient-reported urinary incontinence and erectile dysfunction following radical prostatectomy: results from the European Prostate Centre Innsbruck.

Geiger-Gritsch S, Oberaigner W, Mühlberger N, Siebert U, Ladurner M, Klocker H, Horninger W.

Urol Int. 2015;94(4):419-27. doi: 10.1159/000369475. Epub 2015 Jan 31.

PMID:
25662301
36.

High risk of under-grading and -staging in prostate cancer patients eligible for active surveillance.

Heidegger I, Skradski V, Steiner E, Klocker H, Pichler R, Pircher A, Horninger W, Bektic J.

PLoS One. 2015 Feb 6;10(2):e0115537. doi: 10.1371/journal.pone.0115537. eCollection 2015.

37.

ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells.

Höll M, Koziel R, Schäfer G, Pircher H, Pauck A, Hermann M, Klocker H, Jansen-Dürr P, Sampson N.

Mol Carcinog. 2016 Jan;55(1):27-39. doi: 10.1002/mc.22255. Epub 2015 Jan 5.

38.

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.

Puhr M, Hoefer J, Neuwirt H, Eder IE, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z.

Oncotarget. 2014 Dec 15;5(23):12043-56.

39.

The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening.

Mühlberger N, Heijnsdijk EA, Kurzthaler C, Iskandar R, Krahn MD, Bremner K, Oberaigner W, Klocker H, Horninger W, Conrads-Frank A, Sroczynski G, Siebert U.

Value Health. 2014 Nov;17(7):A559. doi: 10.1016/j.jval.2014.08.1843. Epub 2014 Oct 26. No abstract available.

40.

The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment.

Dueregger A, Heidegger I, Ofer P, Perktold B, Ramoner R, Klocker H, Eder IE.

Nutrients. 2014 Oct 21;6(10):4491-519. doi: 10.3390/nu6104491. Review.

41.

Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer.

Neeb A, Hefele S, Bormann S, Parson W, Adams F, Wolf P, Miernik A, Schoenthaler M, Kroenig M, Wilhelm K, Schultze-Seemann W, Nestel S, Schaefer G, Bu H, Klocker H, Nazarenko I, Cato AC.

Oncotarget. 2014 Sep 30;5(18):8681-9.

42.

A concept of a MIABIS based register of biosample collections at the Medical University of Innsbruck.

Hofer P, Fiegl H, Angerer J, Mueller-Holzner E, Chamson M, Klocker H, Steiner E, Hauffe H, Zschocke J, Goebel G.

Stud Health Technol Inform. 2014;205:293-7.

PMID:
25160193
43.

EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205.

Massoner P, Thomm T, Mack B, Untergasser G, Martowicz A, Bobowski K, Klocker H, Gires O, Puhr M.

Br J Cancer. 2014 Aug 26;111(5):955-64. doi: 10.1038/bjc.2014.366. Epub 2014 Jul 3.

44.

A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.

Köhler A, Demir U, Kickstein E, Krauss S, Aigner J, Aranda-Orgillés B, Karagiannidis AI, Achmüller C, Bu H, Wunderlich A, Schweiger MR, Schaefer G, Schweiger S, Klocker H, Schneider R.

Mol Cancer. 2014 Jun 9;13:146. doi: 10.1186/1476-4598-13-146.

45.

Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis.

Heidegger I, Kern J, Ofer P, Klocker H, Massoner P.

Oncotarget. 2014 May 15;5(9):2723-35.

46.

PGE2 modulates the transcriptional activity of ERRa in prostate stromal cells.

Ning Z, Du X, Zhang J, Yang K, Miao L, Zhu Y, Yuan H, Wang L, Klocker H, Shi J.

Endocrine. 2014 Dec;47(3):901-12. doi: 10.1007/s12020-014-0261-7. Epub 2014 Apr 24.

PMID:
24760659
47.

Epithelial-to-mesenchymal transition and estrogen receptor α mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia.

Shao R, Shi J, Liu H, Shi X, Du X, Klocker H, Lee C, Zhu Y, Zhang J.

Prostate. 2014 Jun;74(9):970-82. doi: 10.1002/pros.22814. Epub 2014 Apr 22.

PMID:
24752964
48.
49.

Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells.

Demir U, Koehler A, Schneider R, Schweiger S, Klocker H.

BMC Cancer. 2014 Jan 31;14:52. doi: 10.1186/1471-2407-14-52.

50.

SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.

Hoefer J, Kern J, Ofer P, Eder IE, Schäfer G, Dietrich D, Kristiansen G, Geley S, Rainer J, Gunsilius E, Klocker H, Culig Z, Puhr M.

Endocr Relat Cancer. 2014 Jan 30;21(2):175-87. doi: 10.1530/ERC-13-0446. Print 2014 Apr.

Supplemental Content

Loading ...
Support Center